Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial

Matti Lehtinen, Dan Apter, Tiina Eriksson, Katja Harjula, Mari Hokkanen, Tuomas Lehtinen, Kari Natunen, Silvia Damaso, Maaria Soila, Dan Bi, Frank Struyf, Matti Lehtinen, Dan Apter, Tiina Eriksson, Katja Harjula, Mari Hokkanen, Tuomas Lehtinen, Kari Natunen, Silvia Damaso, Maaria Soila, Dan Bi, Frank Struyf

Abstract

We studied effectiveness of the AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine against human papillomavirus (HPV) oropharyngeal infections associated with the increase of head/neck cancers in western countries. All 38,631 resident adolescents from 1994 to 1995 birth cohorts of 33 Finnish communities were invited in this community-randomized trial (NCT00534638). During 2008-2009, 11,275 girls and 6,129 boys were enrolled in three arms of 11 communities each. In Arm A, 90% of vaccinated girls/boys, and in Arm B, 90% of vaccinated girls received AS04-HPV-16/18 vaccine. Other Arm A/B and all Arm C vaccinated participants received control vaccine. All Arm A participants and Arm B female participants were blinded to vaccine allocation. Oropharyngeal samples were analyzed from 4,871 18.5-year-old females who attended follow-up visit 3-6 years postvaccination. HPV DNA prevalence was determined by SPF-10 LiPA and Multiplex type-specific PCR. Total vaccine effectiveness (VE) was defined as relative reduction of oropharyngeal HPV prevalence in pooled Arms A/B HPV-vaccinated females vs. all Arm C females. VE against oropharyngeal HPV-16/18, HPV-31/45 and HPV-31/33/45 infections were 82.4% (95% confidence intervals [CI]: 47.3-94.1), 75.3% (95%CI: 12.7-93.0) and 69.9% (95% CI: 29.6-87.1), respectively. In conclusion, the AS04-HPV-16/18 vaccine showed effectiveness against vaccine and nonvaccine HPV-types oropharyngeal infections in adolescent females up to 6 years postvaccination.

Keywords: human papillomavirus; oral infection; oropharyngeal cancer; vaccine effectiveness.

© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

References

    1. de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017;141:664–70.
    1. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancer. J Natl Cancer Inst 2000;92:709–20.
    1. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous‐cell carcinoma of the head and neck. N Engl J Med 2001;344:1125–31.
    1. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embed head and neck specimen. Int J Cancer 2007;121:2465–72.
    1. Haeggblom L, Ramqvist T, Tommasino M, et al. Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub‐site the last 3 years. Papillomavirus Res 2017;4:1–11.
    1. IARC . A review of human carcinogens. Monographs on the evaluation of carcinogenic risks to humans, vol. 100B Lyon: IARC, 2009.
    1. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral‐induced carcinoma? Int J Cancer 2009;125:362–6.
    1. Ramqvist T, Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010;16:1671–7.
    1. Cheraghlou S, Yu PK, Otremba MD, et al. Treatment deintensification in human papillomavirus‐positive oropharynx cancer: outcomes from the National Cancer Data Base. Cancer 2017;124:717–26.
    1. Schroeder L, Wichmann G, Willner M, et al. Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor. Int J Cancer 2017;142:1361–8.
    1. Shah SS, Senapati S, Klacsmann F, et al. Current technologies and recent developments for screening of HPV‐associated cervical and oropharyngeal cancers. Cancers (Basel) 2016;8:E85.
    1. Beachler DC, Kreimer AR, Schiffman M, et al. Costa Rica HPV vaccine trial (CVT) group. Multisite HPV16/18 vaccine efficacy against cervical, anal and oral HPV infection. J Natl Cancer Inst 2016;108:djv302.
    1. Lupato V, Holzinger D, Höfler D, et al. Prevalence and determinants of oral human papillomavirus infection in 500 young adults from Italy. PLoS One 2017;12:e0170091.
    1. Grün N, Mbuya W, Ternhag A, et al. Human papillomavirus prevalence in mouthwashes of patients undergoing tonsillectomy shows dominance of HPV69, without the corresponding finding in the tonsils. Infect Dis 2017;49:588–93.
    1. Rusan M, Klug TE, Henriksen JJ, et al. Prevalence of tonsillar human papillomavirus infections in Denmark. Eur Arch Otorhinolaryngol 2015;272:2505–12.
    1. Handisurya A, Schellenbacher C, Haitel A, et al. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer 2016;114:409–16.
    1. Pinto LA, Kemp TJ, Torres BN, et al. Quadrivalent human papillomavirus (HPV) vaccine induces HPV‐specific antibodies in the oral cavity: results from the mid‐adult male vaccine trial. J Infect Dis 2016;214:1276–83.
    1. Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol 2017;36:262–7.
    1. Lehtinen M, Apter D, Baussano I, et al. Characteristics of a cluster‐randomized, phase IV human papillomavirus vaccination effectiveness trial. Vaccine 2015;33:1284–90.
    1. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV‐16/18 vaccine against the most stringent cervical pre‐cancer end‐points: end‐of study report of a double blind, randomized trial. Lancet Oncol 2012;13:89–99.
    1. Wheeler CM, Castellsagué X, Garland SM, et al. Efficacy of the HPV‐16/18 AS04‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV types (PATRICIA trial). Lancet Oncol 2012;13:100–10.
    1. Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis 2016;22:56–64.
    1. Lehtinen M, Luostarinen T, Vänskä S, et al. Gender‐neutral provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: results of a community randomized trial (III). Int J Cancer 2018;143:2299–31.
    1. Donà MG, Pichi B, Rollo F, et al. Human papillomavirus detection in matched oral rinses, oropharyngeal and oral brushings of cancer‐free high‐risk individuals. Oral Oncol 2019;91:1–6.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir